March « 2014 « Science and Enterprise

Early Trial Shows Wireless Pacemaker Safe, Effective

By Alan, on March 24th, 2014%

Nanostim pacemaker compared in size to Euro coin (St. Jude Medical Inc.)

24 March 2014. Researchers at Mount Sinai Hospital in New York found in an early-stage clinical trial, a smaller and lead-less heart pacemaker could be safely implanted and operate for at least three months without complications. The team led by Mount . . . → Read More: Early Trial Shows Wireless Pacemaker Safe, Effective

FDA Approves Celgene Psoriatic Arthritis Treatment

By Alan, on March 24th, 2014%

(NIH)

24 March 2014. The U.S. Food and Drug Administration on 21 March approved the drug apremilast to treat adults with active cases of psoriatic arthritis. The drug is marketed as Otezla by the pharmaceutical company Celgene in Summit, New Jersey, that also reported results of clinical trials of Otezla to treat the . . . → Read More: FDA Approves Celgene Psoriatic Arthritis Treatment

New Jersey Tech, IT Company to Develop Autism Device

By Alan, on March 21st, 2014%

Screen shot from Face Read 1, an app to help children with autism recognize facial expressions and emotions. (WebTeam Corp.)

21 March 2014. Engineers at New Jersey Institute of Technology in Newark and WebTeam Corp. in Somerset, New Jersey are designing a device to help children with autism spectrum disorders develop basic educational . . . → Read More: New Jersey Tech, IT Company to Develop Autism Device

Process Devised to Generate Stem Cells from Drop of Blood

By Alan, on March 20th, 2014%

(Mattia Belletti/Flickr)

20 March 2014. Researchers at Singapore’s Institute of Molecular and Cell Biology developed a process for deriving adult stem cells from small samples of blood, making it easier for donors to collect and bank their own blood samples. The team led by the institute’s Jonathan Yuin-Han Loh and funded by Singapore’s Agency . . . → Read More: Process Devised to Generate Stem Cells from Drop of Blood

Smartphone App for Point-of-Care Diagnostics in Development

By Alan, on March 20th, 2014%

(Colorimetrix.com)

20 March 2014. Engineers at University of Cambridge in the U.K. designed a smartphone app that accurately performs tests with urine or saliva samples at the point of care. The app, called Colorimetrix, is the work of Leo Martinez-Hurtado, now a postdoctoral researcher at Technical University of Munich and Cambridge Ph.D. candidate . . . → Read More: Smartphone App for Point-of-Care Diagnostics in Development

Genetics Group, Analytics Firm Collaborate on Diagnostics

By Alan, on March 19th, 2014%

(NIST.gov)

19 March 2014. A genetics research center at University of Utah in Salt Lake City and Omicia Inc., a genomic analytics company in Oakland, California are developing systems to make genomic analysis a routine medical diagnostic procedure. The $6 million in funding for the USTAR Center for Genetic Discovery comes from the . . . → Read More: Genetics Group, Analytics Firm Collaborate on Diagnostics

Janssen, Univ. of Alberta Partner on Diabetes Research

By Alan, on March 19th, 2014%

(HHS.gov)

19 March 2014. Janssen Pharmaceutical Companies, a division of Johnson & Johnson, is joining with University of Alberta in Edmonton to fund research on diabetes with commercial potential. The $600,000 fund, with contributions from Janssen and matched by the government of Alberta and Alberta Diabetes Foundation, will support studies on type 1 . . . → Read More: Janssen, Univ. of Alberta Partner on Diabetes Research

Report: Climate Consensus Solid, Sudden Damage Risk Real

By Alan, on March 18th, 2014%

(USGS.gov)

18 March 2014. A new report from American Association for the Advancement of Science (AAAS) underscores the the near-unanimous consensus by scientists that human-caused climate change is happening, and the risks of abrupt and unpredictable damage are increasing. A panel of 10 climate scientists, with partners in the business community, issued the . . . → Read More: Report: Climate Consensus Solid, Sudden Damage Risk Real

Bristol-Myers Squibb, Biotech in Cancer Drug Discovery Deal

By Alan, on March 17th, 2014%

(Wikimedia Commons)

17 March 2014. Bristol-Myers Squibb, a pharmaceutical company in New York, and Five Prime Therapeutics in South San Francisco, California are collaborating in discovery of cancer immunotherapies. The deal can be worth as much as $350 million to Five Prime Therapeutics, in which Bristol-Myers Squibb will also get a 5 percent . . . → Read More: Bristol-Myers Squibb, Biotech in Cancer Drug Discovery Deal

Emergency Room Opioid Prescriptions Jump in 2001-2010

By Alan, on March 14th, 2014%

(FDA.gov)

14 March 2014. Medical researchers at George Washington University in Washington, D.C. found large increases in prescriptions for opioid pain-killers in U.S. hospital emergency rooms over the 2001-2010 decade. The team led by emergency medicine faculty Maryann Mazer-Amirshahi published its findings online yesterday in the journal Academic Emergency Medicine (paid subscription required).

Subscribe for email alerts

Donate to Science & Enterprise

S&E on Mastodon

S&E on LinkedIn

S&E on Flipboard

Like us on Facebook

Specials

Guest Posts

Please share Science & Enterprise